Clinical Trial Update: A PHASE IB STUDY OF IMMUNOTHERAPY WITH EX VIVO PRE-ACTIVATED AND EXPANDED CB-NK CELLS IN COMBINATION WITH CETUXIMAB, IN COLORECTAL CANCER PATIENTS WITH MINIMAL RESIDUAL DISEASE (MRD) [Phase 1]

View source ↗

Summary

Phase 1 trial evaluating immunotherapy using ex vivo pre-activated and expanded CB-NK cells in combination with cetuximab for colorectal cancer patients with mi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• CB-NK cells
• Cetuximab (cetuximab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Colon Cancer, Resected Stage | Phase 1 | Status: COMPLETED